|

Add a bookmark to get started

Laura Moore

Laura Moore LLM MSc

She/herAsociada
Vast experience in the life sciences patent and SPC litigation field. The teams' practical advice ensures we and our clients always remain several steps ahead of competitors.
Legal 500 2024
About
Laura Moore is an Associate in the Intellectual Property & Technology group, advising on all aspects of intellectual property, with a particular focus on multi-jurisdictional patent litigation.
Professional QualificationsSolicitor regulated by the Law Society of Ireland

EXPERIENCE

  • BioNTech in patent infringement and validity proceedings before the Commercial Court. The proceedings relate to the alleged infringement of two European Patents by BioNTech's/Pfizer's Covid-19 vaccine which is sold under the Comirnaty brand.
  • Janssen Biotech Inc./Johnson & Johnson in proceedings before the Commercial Court including Preliminary Injunction proceedings brought against Amgen in Ireland relating to Janssen’s top selling medicine Stelara. These were the first proceedings taken in the European Union relating to a derogation sought under the 2019 SPC manufacturing and stockpiling waiver.
  • Merck Sharp & Dohme LLC and Merck Sharp & Dohme Ireland (Human Health) Limited (together "MSD") in proceedings brought by Merck KGaA & Ors. alleging breach of contract, trademark infringement and passing off. The Irish proceedings are part of long standing multi-national litigation between the parties over the use of the name “MERCK”.
  • Merck Sharp & Dohme in patent/SPC infringement proceedings before the Commercial Court including preliminary injunction proceedings against Mylan restraining Mylan from offering, putting on the market or using products containing sitagliptin and metformin (Janumet) used to treat type 2 diabetes. Secured a preliminary injunction against Mylan in January 2023 which was upheld on Appeal in April 2023. 
  • Novartis AG in two sets of proceedings before the Commercial Court (IP and Technology List) against Mylan and Accord relating to patents that protect Gilenya (fingolimod). 
  • Merck Sharp & Dohme in patent infringement proceedings against Clonmel Healthcare Ltd at the CJEU. This referral related to correct the interpretation of Articles 3(a) and (c) of the SPC Regulations concerning MSD’s Supplementary Protection Certificate for a combination drug Inegy used in cholesterol treatment. 
Languages
  • Inglés
Education
  • University College Dublin, Master of Science – Sustainable Development (MSc), 2022
  • Carlow Institute of Technology, Certificate in Data Protection, 2020
  • University College Dublin/Maastricht University, Master of Laws – Intellectual Property & Technology (LLM), 2019
  • Trinity College Dublin, Bachelor of Laws (LLB), 2018

Prior Experience

  • Completed her training contract in a Tier 1 Intellectual Property Firm, 2021-2024

Connect